Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...
President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...
By focusing on chips and pharmaceuticals, Trump could squeeze US allies in Asia, including Taiwan, South Korea and Japan.
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...
In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
Japanese pharmaceutical company Eisai Co and U.S. firm Biogen Inc said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback